國家衛生研究院 NHRI:Item 3990099045/11193
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 857833      Online Users : 837
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/11193


    Title: Evaluation of total and IgA-specific antibody targeting Epstein-Barr virus glycoprotein 350 and nasopharyngeal carcinoma risk
    Authors: Coghill, AE;Bu, W;Hsu, WL;Nguyen, H;Yu, KJ;Chien, YC;Chen, CJ;Cohen, JI;Hildesheim, A
    Contributors: National Institute of Cancer Research
    Abstract: Background: We previously reported that higher levels of antibody targeting EBV glycoprotein350 (gp350), an EBV vaccine candidate, were protective against nasopharyngeal carcinoma (NPC) in genetically high-risk families from Taiwan. The current study attempted to extend this association to a general population cohort. Methods: We compared total and IgA-specific gp350 antibody levels in 35 incident NPC cases and 81 disease-free controls from the Cancer Screening Program in Taiwan (23,943 individuals recruited from 1991-1992). Luciferase immunoprecipitation (LIPS) assays were used to quantify gp350 antibody levels. Results: Total EBVgp350 antibody levels were not higher in individuals who remained disease-free compared to those who developed NPC (P=0.11). This lack of a protective gp350 association persisted for cases diagnosed >5 years (OR=1.05; P=0.91) and <5 years (OR=1.85; P=0.40) after blood draw. In addition, IgA-specific gp350 antibody levels were higher in cases compared to controls (OR=7.03; P=0.001). This increased risk was most pronounced for cases diagnosed <5 years after blood draw (OR=11.7; P=0.004). Conclusion: Unlike our prior findings in those with a strong family history of NPC, total gp350 antibody levels were not protective against NPC development in this general population setting.
    Date: 2018-09
    Relation: Journal of Infectious Disease. 2018 Sep;218(6):886-891.
    Link to: http://dx.doi.org/10.1093/infdis/jiy250
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0022-1899&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000441792600006
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85055114802
    Appears in Collections:[Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB29718378.pdf532KbAdobe PDF271View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback